To advance a clinically-translatable therapeutic paradigm, we prioritized the study of parameters assessing anti-cancer efficacy of DEspR-inhibition at the cellular level in vitro, and subject overall survival in vivo. The gene discussed is FBXW7-AS1; the disease is cancer.